|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.
|
29754146 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Luciferase reporter assay, RT‑qPCR and western blot analysis further demonstrated that E2F3 was a direct target of miR‑433 in NSCLC.
|
29767254 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Our findings suggested that FLVCR1-AS1/miR-573/E2F3 axis was an important signaling pathway in mediating tumorigenesis and progression of NSCLC, and further indicated that FLVCR1-AS1 could be a novel diagnostic biomarker and therapeutic target for NSCLC.
|
30309647 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
These results suggested that NEAT1 may promote the development of NSCLC through the miR-377-3p-E2F3 pathway.
|
29085511 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these observations imply that the NEAT1 modulated the expression of E2F3 gene by acting as a ceRNA, which may build up the missing link between the regulatory miRNA network and NSCLC progression.
|
27351135 |
2016 |
|
Focal glomerulosclerosis
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Pathogenesis of focal segmental glomerular sclerosis in a girl with the partial deletion of chromosome 6p.
|
21372519 |
2011 |
|
Intellectual Disability
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Pathogenesis of focal segmental glomerular sclerosis in a girl with the partial deletion of chromosome 6p.
|
21372519 |
2011 |
|
Focal Segmental Glomerulosclerosis, Not Otherwise Specified
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Pathogenesis of focal segmental glomerular sclerosis in a girl with the partial deletion of chromosome 6p.
|
21372519 |
2011 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of miR-194-5p and E2F transcription factor 3 (E2F3) were determined by means of quantitative reverse transcription and polymerase chain reaction in BC specimens.
|
30570877 |
2019 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of miR-194-5p and E2F transcription factor 3 (E2F3) were determined by means of quantitative reverse transcription and polymerase chain reaction in BC specimens.
|
30570877 |
2019 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Mapping eGFR loci to the renal transcriptome and phenome in the VA Million Veteran Program.
|
31451708 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results suggested that E2F3 might play a tumour-promoting role in the metastasis and progression of GC by regulating the miR-125a/DKK3 axis.
|
31423109 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
E2F3, a member of the E2F family, plays a critical role in cell cycle and proliferation by targeting downstream, retinoblastoma (RB) a tumor suppressor family protein.
|
31839743 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these results suggest that miR‑210‑3p may act as a tumor suppressor in ovarian cancer cells and affect the sensitivity of cells to cisplatin by directly targeting E2F3.
|
30957179 |
2019 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of miR-194-5p and E2F transcription factor 3 (E2F3) were determined by means of quantitative reverse transcription and polymerase chain reaction in BC specimens.
|
30570877 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
By regulating E2F3, miR-194-5p inhibited cell migration and invasion in BC.
|
30570877 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MicroRNA‑433 reduces cell proliferation and invasion in non‑small cell lung cancer via directly targeting E2F transcription factor 3.
|
29767254 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, the inhibitory effects of miR-152 on OS growth and invasion were attenuated by E2F3 overexpression.
|
28810933 |
2018 |
|
Serum total cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A large electronic-health-record-based genome-wide study of serum lipids.
|
29507422 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
E2F3 is a transcription factor that has been shown to be overexpressed in hepatocellular carcinoma (HCC).
|
29135049 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated how Rb is integrated to control bladder cancer progression through E2F3 and p53 regulation.
|
27922689 |
2017 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated how Rb is integrated to control bladder cancer progression through E2F3 and p53 regulation.
|
27922689 |
2017 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Latest reports discovered intricate networks between microRNAs (miRNAs) and E2F3 in regulating the balance of these events, including proliferation, apoptosis, metastasis, as well as drug resistance. miRNAs are non-coding small RNAs which negatively regulate gene expressions post-transcriptionally mainly through 3'-UTR binding of target mRNAs.
|
28947999 |
2017 |